Last Modified: October 15, 2004
Conference Date: December 11, 2004
Conference Location: San Francisco, CA
Conference Date: January 8, 2005
Conference Location: Atlanta, GA
Conference Date: February 5, 2005
Conference Location: Philadelphia, PA
Conference Web Page URL: www.thecbce.com/futureprograms.asp
Topics Covered: This continuing medical education (CME) activity will compare the biology, clinical efficacy, and toxicity of small-molecule EGFR inhibitors in the treatment of NSCLC.
Who Should Attend: This activity is designed primarily for medical oncologists and other physicians interested in the treatment of cancer.
Continuing Education: Yes
Apr 9, 2014 - For patients with non-small-cell lung cancer and wild-type epidermal growth factor receptor (EGFR) mutations, conventional chemotherapy improves progression-free survival better than first-generation EGFR tyrosine kinase inhibitors, according to research published in the April 9 issue of the Journal of the American Medical Association.
Jul 29, 2011
Jun 24, 2010